002399 Stock Overview Shenzhen Hepalink Pharmaceutical Group Co., Ltd. More details
Rewards Risk Analysis No risks detected for 002399 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shenzhen Hepalink Pharmaceutical Group Historical stock prices Current Share Price CN¥10.94 52 Week High CN¥12.54 52 Week Low CN¥6.89 Beta 0.46 1 Month Change -1.17% 3 Month Change 5.19% 1 Year Change -6.73% 3 Year Change -36.02% 5 Year Change -43.90% Change since IPO -80.01%
Recent News & Updates See more updates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Business Is Trailing The Industry But Its Shares Aren't Dec 06
Price target increased by 14% to CN¥7.30 Nov 20
Third quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.014 in 3Q 2023) Oct 31
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt Oct 07
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.039 in 2Q 2023) Aug 31
Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio Aug 22
Price target increased by 8.1% to CN¥6.70 Jul 16
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2024 Jul 12
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 29
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt Jun 12
Less than half of directors are independent May 17
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues May 06
First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.045 in 1Q 2023) Apr 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2024 Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 29
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SEHK:9989) dropped from FTSE All-World Index (USD) Mar 18
New minor risk - Financial data availability Mar 17
Price target decreased by 16% to CN¥7.10 Feb 19
Investor sentiment deteriorates as stock falls 16% Feb 02
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023 Feb 01
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Consensus EPS estimates fall by 10% Dec 21 Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SZSE:002399) dropped from Shenzhen Stock Exchange Component Index
New minor risk - Profit margin trend Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.096 in 3Q 2022) Nov 01
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 30, 2023 Oct 17
Second quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.19 in 2Q 2022) Aug 31
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen Juan Aug 22
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023 Jul 12
Consensus revenue estimates fall by 11% Jun 17
Price target decreased by 42% to CN¥9.10 Jun 16
Less than half of directors are independent May 26
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022 May 26 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Directorate Changes
Consensus EPS estimates fall by 13% Apr 07
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2022 Results on Mar 31, 2023
Price target decreased to CN¥17.40 Nov 16
Consensus EPS estimates fall by 14% Nov 04
Third quarter 2022 earnings released Oct 29
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022 Oct 15
Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in 2Q 2021) Aug 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 28 July 2022 Jul 22 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2021 Jun 14
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Final Dividend on H Share for the Year Ended December 31, 2021, Payable on August 15, 2022 Jun 11
Investor sentiment improved over the past week May 10
First quarter 2022 earnings: EPS misses analyst expectations May 02
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Executive Changes May 02
Price target decreased to CN¥14.60 Apr 27
Less than half of directors are independent Apr 27
Price target decreased to CN¥14.60 Apr 20 Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 10, 2022
Full year 2021 earnings: EPS and revenues miss analyst expectations Apr 01
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2021 Jan 30
Less than half of directors are independent Oct 29
Third quarter 2021 earnings released: EPS CN¥0.084 (vs CN¥0.092 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.26 in 2Q 2020) Aug 27
Investor sentiment improved over the past week Aug 04
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces "Inhixa" Obtains Approval from Bosnia and Herzegovina Jun 11
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2020 May 29
Vice Chairman of the Board Xuan Sun has left the company May 13
First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.20 in 1Q 2020) Apr 30
Non-Executive Director has left the company Apr 21
Price target decreased to CN¥23.74 Apr 09
Consensus revenue estimates fall to CN¥6.22b Apr 05
Full year 2020 earnings released: EPS CN¥0.76 (vs CN¥0.85 in FY 2019) Mar 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 Feb 25
New 90-day high: CN¥20.17 Feb 18
New 90-day low: CN¥16.81 Dec 28
New 90-day low: CN¥18.08 Dec 12
New 90-day low: CN¥19.24 Nov 25
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue and earnings miss expectations Oct 30
New 90-day low: CN¥21.57 Oct 22
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020 Oct 17
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Joint Company Secretary of the Company and an Authorized Representative Changes Sep 19
New 90-day low - CN¥22.22 Sep 09
Analysts increase EPS estimates to CN¥0.83 Sep 04
First half earnings released Aug 29
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020 Aug 13
New 90-day high - CN¥27.90 Aug 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 4.049739 billion. Jul 08 Shareholder Returns 002399 CN Pharmaceuticals CN Market 7D -3.2% -1.9% -0.6% 1Y -6.7% -5.7% 8.3%
See full shareholder returns
Return vs Market: 002399 underperformed the CN Market which returned 9.2% over the past year.
Price Volatility Is 002399's price volatile compared to industry and market? 002399 volatility 002399 Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 7.3% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.9% 10% least volatile stocks in CN Market 5.6%
Stable Share Price: 002399 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002399's weekly volatility (6%) has been stable over the past year.
About the Company Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Show more Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary How do Shenzhen Hepalink Pharmaceutical Group's earnings and revenue compare to its market cap? 002399 fundamental statistics Market cap CN¥14.47b Earnings (TTM ) -CN¥146.31m Revenue (TTM ) CN¥5.45b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 002399 income statement (TTM ) Revenue CN¥5.45b Cost of Revenue CN¥4.50b Gross Profit CN¥953.36m Other Expenses CN¥1.10b Earnings -CN¥146.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.10 Gross Margin 17.49% Net Profit Margin -2.68% Debt/Equity Ratio 34.8%
How did 002399 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 17:23 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Lei Tian AJ Securities Co., Ltd Peng Yan Changjiang Securities Co. LTD. Diandian Li China Merchants Securities Co. Ltd.
Show 7 more analysts 
